The Philadelphia HIV Therapeutic and Prevention Clinical Trials Unit (Philadelphia HIV CTU-PHCTU) will provide the administrative infrastructure and scientific leadership to advance the science of HIV treatment and prevention within the five proposed HIV Research Networks, Adult Therapeutics, Therapeutics in Pediatric and Maternal Populations, Integrated Prevention, Vaccines, and Microbicides through four specific research aims:
Specific Aim 1. Participate in the creation and implementation of the scientific agenda of the HIV Research Networks through committee and protocol team membership and through initiation of new Network science.
Specific Aim 2. Participate in the implementation of the scientific agenda of the HIV Research Networks through the cost efficient conduct of clinical trials.
Specific Aim 3. Train and mentor the next generation of HIV investigators. By engaging fellows and junior faculty in protocol development, educational conferences and clinical trials, the PHCTU will actively recruit and train the next generation of HIV investigators.
Specific Aim 4. Educate the Philadelphia medical, scientific and HIV-affected communities about advances in HIV therapy and prevention. The Philadelphia HIV CTU will help to coordinate and advertise the HIV-related medical and scientific forums that currently exist, and will continue to seek input from the HIV-affected community through its Community Advisory Board and through educational outreach to HIV affected groups. The Philadelphia HIV CTU will feature an integrated, efficient clinical trials structure with four clinical research sites, three on the University of Pennsylvania (University of Pennsylvania Perelman School of Medicine-PSOM and The Children's Hospital of Philadelphia- CHOP) medical campus and one on the Drexel University medical campus, including two sites that will focus on adult HIV therapeutic trials, one that will focus on adult prevention trials, and one that will focus on trials involving pediatric ad adolescent populations.
Despite numerous advances in the understanding of HIV pathogenesis, the realization of effective antiretroviral therapy (ART), and the widening scope of HIV prevention strategies, many challenges remain in the domains of HIV treatment and prevention that will need to be studied in adult, adolescent, and pediatric populations.
|Salantes, D Brenda; Zheng, Yu; Mampe, Felicity et al. (2018) HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest 128:3102-3115|
|Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:|
|Benson, Constance A; Andersen, Janet W; Macatangay, Bernard J C et al. (2018) Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis 67:1712-1719|
|MacBrayne, Christine E; Marks, Kristen M; Fierer, Daniel S et al. (2018) Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother 73:2112-2119|
|Li, Shuying S; Kochar, Nidhi K; Elizaga, Marnie et al. (2017) DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. Clin Vaccine Immunol 24:|
|Spitsin, Sergei; Tebas, Pablo; Barrett, Jeffrey S et al. (2017) Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. JCI Insight 2:|
|Muhammad, Josh; Chan, Ellen S; Brown, Todd T et al. (2017) Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation. Open Forum Infect Dis 4:ofx210|
|Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med 167:384-393|
|Bisson, Gregory P; Ramchandani, Ritesh; Miyahara, Sachiko et al. (2017) Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS 31:2217-2225|
|Beigel, John H; Tebas, Pablo; Elie-Turenne, Marie-Carmelle et al. (2017) Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5:500-511|
Showing the most recent 10 out of 61 publications